COMMUNIQUÉS West-GlobeNewswire

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
30/10/2025
SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients [...]
Primary Care Physician Use of Counterpart Assistant (CA) Technology Associated With Earlier Diagnosis And Less Frequent Hospitalization In Underserved Populations
30/10/2025
New whitepaper demonstrates how CA enables primary care teams in resource-constrained settings to prevent, detect, and manage chronic disease. SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“ [...]
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
30/10/2025
SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Conseil d’administration
30/10/2025
Châtillon, France, 30 octobre 2025 DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Conseil d’administration DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (la « [...]
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
30/10/2025
Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV [...]
Corbus Pharmaceuticals Announces Proposed Public Offering
30/10/2025
NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to offer and sell shares [...]
Rapid Micro Biosystems to Participate in the Stifel 2025 Healthcare Conference
30/10/2025
LEXINGTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]
MEDIROM MOTHER Labs Inc. Receives Capital Investment from Internal Investors
30/10/2025
Completion of Private Placement of New Shares as Part of Series A Round Valued at ¥9 Billion TOKYO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MEDIROM MOTHER Labs Co., Ltd. (Headquarters: Minato-ku, Tokyo; President and CEO: [...]
Nyxoah Publiera ses Résultats Financiers du Troisième Trimestre 2025 le 13 Novembre 2025
30/10/2025
Nyxoah Publiera ses Résultats Financiers du Troisième Trimestre 2025 le 13 Novembre 2025 Mont-Saint-Guibert, Belgique – 30 octobre 2025, 22h10 CET / 17h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou [...]
Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025
30/10/2025
Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025 Mont-Saint-Guibert, Belgium – Thursday, October 30, 2025, 10:10pm CET / 5:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the [...]
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
30/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Bright Minds Biosciences to Present at Upcoming Conferences
30/10/2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the [...]
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
31/10/2025
Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patients LA JOLLA, Calif., Oct. 30, 2025 (GLOBE [...]
Nkarta to Participate in November Investor Conferences
30/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its [...]
‘Do I Qualify for Lung Cancer Screening?’: Understanding Your Path to Early Detection Could Save Your Life
30/10/2025
While other organized screening programs are well-established, organized lung cancer screening remains less familiar to many Canadians, yet it’s a crucial and accessible way to protect your health. Lung Health [...]
CROSSJECT annonce la mise à disposition du rapport financier semestriel au 30 juin 2025
30/10/2025
Communiqué de presse CROSSJECT annonce la mise à disposition du rapport financier semestriel au 30 juin 2025 DIJON, France – 30 octobre 2025 (20H00 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société [...]
GENFIT annonce son intention de procéder au retrait volontaire de la cotation de ses « American Depositary Shares » sur le Nasdaq Global Select Market
30/10/2025
La décision de GENFIT de retrait du Nasdaq traduit une volonté stratégique de simplifier sa structure organisationnelle et d'améliorer son efficacité opérationnelle Les actions de GENFIT restent cotées sur le marché [...]
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market
30/10/2025
GENFIT’s decision to delist from Nasdaq reflects strategic intent to simplify corporate structure and improve operational efficiency GENFIT remains listed on the regulated market of Euronext Paris as its primary trading [...]
TME Pharma publie ses résultats semestriels et son rapport de mi-année
30/10/2025
TME Pharma publie ses résultats semestriels et son rapport de mi-année Berlin, Allemagne, 30 octobre 2025, 21h00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), Une société de biotechnologie en phase clinique, [...]

Pages